Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials.
Avihingsanon A, Chetchotisakd P, Kiertiburanakul S, Ratanasuwan W, Siripassorn K, Supparatpinyo K, Martin H, Wang H, Wong T, Wang HY. Avihingsanon A, et al. Among authors: kiertiburanakul s. HIV Med. 2023 Mar;24(3):290-300. doi: 10.1111/hiv.13386. Epub 2022 Aug 17. HIV Med. 2023. PMID: 36912172
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B; Staccato Study Group. Ananworanich J, et al. Among authors: kiertiburanakul s. Antivir Ther. 2005;10(6):761-7. Antivir Ther. 2005. PMID: 16218176 Clinical Trial.
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.
Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genné D, Nüesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B; Staccato Study Group; Swiss HIV Cohort Study. Ananworanich J, et al. Among authors: kiertiburanakul s. Lancet. 2006 Aug 5;368(9534):459-65. doi: 10.1016/S0140-6736(06)69153-8. Lancet. 2006. PMID: 16890832 Clinical Trial.
Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K; Staccato Study Team. Ananworanich J, et al. Among authors: kiertiburanakul s. Antivir Ther. 2006;11(5):631-5. Antivir Ther. 2006. PMID: 16964832 Clinical Trial.
Prevalence of thyroid dysfunction in Thai HIV-infected patients.
Ketsamathi C, Jongjaroenprasert W, Chailurkit LO, Udomsubpayakul U, Kiertiburanakul S. Ketsamathi C, et al. Among authors: kiertiburanakul s. Curr HIV Res. 2006 Oct;4(4):463-7. doi: 10.2174/157016206778560036. Curr HIV Res. 2006. PMID: 17073621
High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant.
Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Horsakulthai M, Chasombat S, Ruxrungtham K; Study Team. Chetchotisakd P, et al. Among authors: kiertiburanakul s. J Int Assoc Physicians AIDS Care (Chic). 2006 Dec;5(4):152-6. doi: 10.1177/1545109706294288. J Int Assoc Physicians AIDS Care (Chic). 2006. PMID: 17101807
Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K; Study Team. Chetchotisakd P, et al. Among authors: kiertiburanakul s. HIV Med. 2007 Nov;8(8):529-35. doi: 10.1111/j.1468-1293.2007.00506.x. HIV Med. 2007. PMID: 17944686 Free article. Clinical Trial.
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523. J Infect Dis. 2008. PMID: 18476293 Clinical Trial.
258 results